News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Halt Medical, Inc. Release: the Acessa™ System Wins Gold in the 15th Annual Medical Design Excellence Awards Competition


6/25/2013 10:18:02 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LIVERMORE, Calif., June 25, 2013 /PRNewswire/ -- Halt Medical, Inc. is proud to announce that the Acessa System was awarded Gold in the radiological and electromechanical devices category at the 15th Annual Medical Design Excellence Awards competition. The Acessa System is the only medical device with a specific indication for the treatment of uterine fibroids.

"The Medical Design Excellence Awards honor the highest caliber medical devices on the market today," said Jeffrey M. Cohen, Halt Medical CEO. "We are delighted to celebrate the collaboration and success of our R&D, Clinical, Operations and supplier teams."

Added Russ DeLonzor, Halt Medical President and COO, "Rick Spero, Vice President of R&D, and his team have done a fabulous job in leading the design and development of the Acessa System. This continues to be validated by the many satisfied physicians adopting the technology and their patients who enjoy significant improvements in quality of life."

The highly competitive annual Medical Design Excellence Awards competition is sponsored by Medical Device + Diagnostic Industry magazine. MD+DI serves the industry as the leading source of in-depth news and information to help industry professionals develop, design, and manufacture medical products that comply with complex and demanding regulations and market requirements.

The Acessa System is used in a minimally invasive laparoscopic procedure that delivers radiofrequency energy to destroy the fibroids. After treatment, the fibroid is re-absorbed by the surrounding tissue. Acessa allows the surgeon to treat only the fibroids, while preserving normal function of the uterus. Patients typically go home the same day with little pain, and enjoy a rapid return to normal activities. More than 300 women have been successfully treated with Acessa.

In addition to those at Halt who worked hard to design this standard-of-care changing technology, Halt Medical thanks CullDez Product Development (Livermore, CA), Aim Design (Brentwood, CA), Dean Miller Associates (Menlo Park, CA), Bruxton Corporation (Seattle, WA), and Know-How Consulting (Honolulu, HI).

About Halt Medical, Inc.

Founded in 2004, Halt Medical is a medical device company focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Company has developed and launched the Acessa System and Procedure, using radiofrequency energy to destroy uterine fibroids. The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Acessa System also has regulatory approval to treat symptomatic uterine fibroids in the European Union, Canada, and Mexico. The Company is located in Brentwood, CA. For information about the Acessa System, please visit www.haltmedical.com. To connect with Halt Medical on Facebook visit www.facebook.com/acessasystem or on Twitter at www.twitter.com/acessasystem.

SOURCE Halt Medical, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES